0000899243-20-028167.txt : 20201014 0000899243-20-028167.hdr.sgml : 20201014 20201014160510 ACCESSION NUMBER: 0000899243-20-028167 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201010 FILED AS OF DATE: 20201014 DATE AS OF CHANGE: 20201014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38137 FILM NUMBER: 201239113 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER NAME: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001662524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472608175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 617-207-0202 MAIL ADDRESS: STREET 1: 22 BOSTON WHARF RD STREET 2: 9TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-10-10 0 0001662524 AKCEA THERAPEUTICS, INC. AKCA 0000874015 IONIS PHARMACEUTICALS INC 2855 GAZELLE COURT CARLSBAD CA 92010 0 0 1 0 Common Stock 2020-10-10 4 P 0 21237715 18.15 A 98322397 I See Footnote Pursuant to an Agreement and Plan of Merger dated as of August 30, 2020, on September 14, 2020, Avalanche Merger Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. ("Parent"), commenced a tender offer (the "Offer") to purchase all of the outstanding shares of common stock of Akcea Therapeutics, Inc. ("Akcea") at a purchase price of $18.15 per share. As of the expiration of the Offer at one minute after 11:59 p.m., Eastern Time, on October 9, 2020, 21,237,715 shares had been tendered and not validly withdrawn pursuant to the Offer. Purchaser accepted for purchase all shares tendered and not validly withdrawn pursuant to the Offer. This number reflects 77,094,682 shares owned directly by Parent and 21,237,715 shares, which were tendered in the Offer and accepted for purchase on October 10, 2020, and thereupon owned by Purchaser. Following Purchaser's acceptance for purchase of shares tendered in the Offer, on October 12, 2020, Purchaser was merged with and into Akcea, with Akcea surviving the merger as a wholly owned subsidiary of Parent. /s/ Elizabeth L. Hougen, Executive Vice President, Finance and Chief Financial Officer of Ionis Pharmaceuticals, Inc. 2020-10-14